We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+7.98%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$6.25B
AUM Growth
-$1.7B
Cap. Flow
-$2.08B
Cap. Flow %
-33.31%
Top 10 Hldgs %
54.24%
Holding
331
New
77
Increased
88
Reduced
65
Closed
73

Top Buys

Rank Stock Value
1
FIVN icon
FIVE9
FIVN
+$41.6M
2
NARI
Inari Medical, Inc. Common Stock
NARI
+$39M
3
DPZ icon
Domino's
DPZ
+$33.2M
4
INCY icon
Incyte
INCY
+$27.6M
5
HUM icon
Humana
HUM
+$26.5M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$109M
2
EXAS
Exact Sciences
EXAS
+$59.2M
3
SNY icon
Sanofi
SNY
+$49.7M
4
KDP icon
Keurig Dr Pepper
KDP
+$49.6M
5
GSK icon
GSK
GSK
+$39.9M

Sector Composition

Rank Sector Weight
1 Healthcare 41.55%
2 Consumer Discretionary 7.13%
3 Consumer Staples 5.35%
4 Technology 5.24%
5 Communication Services 0.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BJRI icon
126
BJ's Restaurants
BJRI
$1.48B
$4.88M 0.08%
150,000
+75,000
+100% +$2.42M
ALUR
127
DELISTED
Allurion Technologies
ALUR
$4.79M 0.08%
+312,240
New +$6.09M
BSX icon
128
Boston Scientific
BSX
$71.7B
$4.76M 0.08%
56,855
+33,555
+144% +$2.65M
RVPH
129
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
$4.59M 0.07%
+159,300
New +$3.54M
HYPD
130
Hyperion DeFi Inc
HYPD
$40.3M
$4.41M 0.07%
106,679
+30,921
+41% +$1.99M
VSTM icon
131
Verastem
VSTM
$509M
$4.08M 0.07%
+1,364,000
New +$3.7M
SYRE icon
132
Spyre Therapeutics
SYRE
$9B
$4M 0.06%
136,000
– –
RSI icon
133
Rush Street Interactive
RSI
$2.94B
$3.8M 0.06%
+350,000
New +$3.38M
LEN icon
134
Lennar Class A
LEN
$20.4B
$3.76M 0.06%
20,696
-8,630
-29% -$1.45M
ONDS icon
135
Ondas Inc
ONDS
$5.02B
$3.66M 0.06%
+4,750,000
New +$3.9M
CTXR icon
136
Citius Pharmaceuticals
CTXR
$18.2M
$3.64M 0.06%
291,040
-115,200
-28% -$1.94M
FDMT icon
137
4D Molecular Therapeutics
FDMT
$546M
$3.63M 0.06%
+336,000
New +$5.58M
ENLV icon
138
Enlivex Ltd
ENLV
$33.3M
$3.59M 0.06%
142,600
+29,229
+26% +$595K
AXDX
139
DELISTED
Accelerate Diagnostics
AXDX
$3.59M 0.06%
2,101,000
+493,000
+31% +$730K
NPCE icon
140
Neuropace
NPCE
$484M
$3.35M 0.05%
+480,000
New +$3.51M
PMN icon
141
ProMIS Neurosciences
PMN
$122M
$3.34M 0.05%
+106,800
New +$3.99M
MUSA icon
142
Murphy USA
MUSA
$10.1B
$3.25M 0.05%
+6,592
New +$3.31M
SCLX icon
143
Scilex Holding
SCLX
$48.2M
$3.25M 0.05%
100,286
-241,143
-71% -$11.6M
CLNN icon
144
Clene
CLNN
$67.9M
$3.13M 0.05%
+682,374
New +$3.59M
MLCO icon
145
Melco Resorts & Entertainment
MLCO
$2.15B
$3.12M 0.05%
+400,000
New +$2.36M
W icon
146
Wayfair
W
$14.4B
$3.09M 0.05%
55,000
-38,000
-41% -$1.83M
AISP
147
Airship AI Holdings
AISP
$66.5M
$2.99M 0.05%
+1,300,000
New +$4.21M
TTOO
148
DELISTED
T2 Biosystems, Inc
TTOO
$2.75M 0.04%
1,396,000
-262,000
-16% -$994K
ALGS icon
149
Aligos Therapeutics
ALGS
$33M
$2.73M 0.04%
315,095
+24,839
+9% +$309K
KYNB
150
Kyntra Bio
KYNB
$28.3M
$2.72M 0.04%
272,000
-85,440
-24% -$1.29M
4 5
6
7 8

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return
DSC
Donald Smith & Co New York $5.56B AUM 47.13% 1-Year Est. Return
ACM
Altimeter Capital Management Boston, Massachusetts $5.7B AUM 36.74% 1-Year Est. Return
PI
PGGM Investments Zeist, Netherlands $5.7B AUM 17.05% 1-Year Est. Return

Armistice Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Armistice Capital held 331 positions worth $6.25B, down 21% from $7.95B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Armistice Capital withdrew a net $2.08B in Q3 2024, closing 73 positions and reducing 65 holdings. Its most notable exit was Exact Sciences, an estimated $59.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 33% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

Against the trend, Armistice Capital opened a new position in Paramount Global Class B worth $21.2M.

  • Armistice Capital's largest Q3 2024 buy was Paramount Global Class B: 2,000,000 shares worth $21.2M.
  • Armistice Capital added most to FIVE9 in Q3 2024, an estimated $41.6M increase.
  • Armistice Capital's biggest Q3 2024 reduction was Neurocrine Biosciences, cutting an estimated $109M.
  • Armistice Capital fully exited Exact Sciences in Q3 2024, selling an estimated $59.2M.
  • Armistice Capital's ten largest holdings make up 54% of its $6.25B portfolio in Q3 2024.
  • Armistice Capital opened 77 new positions and closed 73 in Q3 2024.
  • Armistice Capital's portfolio value fell 21% quarter-over-quarter to $6.25B.

Based on Armistice Capital's 13F filing for Q3 2024, filed 14 Nov 2024.